Trimas Corp. (TRS) Tops Q2 EPS by 6c; Boosts FY12 Sales Growth Outlook
Tweet
Share
E-mailGet Alerts TRS Hot Sheet
Price: $38.70 --0%
Financial Fact:
Continuing operations: 0.19
Today's EPS Names:
OTLK, EGRX, MOVE, More
Financial Fact:
Continuing operations: 0.19
Today's EPS Names:
OTLK, EGRX, MOVE, More
Join SI Premium – FREE
Trimas Corp. (NASDAQ: TRS) reported Q2 EPS of $0.61, $0.06 better than the analyst estimate of $0.55. Revenue for the quarter came in at $338.4 million versus the consensus estimate of $324.23 million.
Trimas raised its 2012 sales outlook from an increase of 7% to 10% to a range of 10% to 14% compared to 2011.
For earnings history and earnings-related data on Trimas Corp. (TRS) click here.
Trimas raised its 2012 sales outlook from an increase of 7% to 10% to a range of 10% to 14% compared to 2011.
For earnings history and earnings-related data on Trimas Corp. (TRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
- Instil Bio Inc. (TIL) Misses Q2 EPS by 21c
- Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
